噬菌体抗菌治疗安全性评估体系的建立
作者:
基金项目:

优秀医学青年人才A类计划(06N1702002);国家青年科学基金(31500154);上海市卫生和计划生育委员会(201440289)


Establishment of safety assessment system of phage therapy
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [20]
  • |
  • 相似文献 [20]
  • |
  • 引证文献
  • | |
  • 文章评论
    摘要:

    人类已经进入后抗生素时代,噬菌体治疗近年来重新备受重视,噬菌体制剂不同于传统抗菌药物,已有对传统抗菌药物的安全性评估体系不适合用于对噬菌体治疗制剂的评估,需要建立对噬菌体治疗安全性评估的体系。本文就噬菌体治疗所涉及的安全性问题进行系统分析研究,通过噬菌体本身的选择、噬菌体制剂制备、制剂形式、制剂给予途径、剂量和频次等,以及噬菌体治疗细菌感染性疾病患者选择等所涉及的安全性和噬菌体治疗对周围微环境的影响等进行全面分析。建立噬菌体治疗安全性评估体系,为噬菌体治疗尽早进入临床奠定基础。

    Abstract:

    We have entered into post-antibiotic era, phage therapy has been refocused recently, bacteriophages are different from the normal antibiotics. It is unsuitable to use the established safety assessment system for classical antimicrobial agents to evaluate the safety of bacteriophages for therapy. So, it is necessary to establish the safety assessment system of phage therapy involved in the whole procedures of choosing bacteriophages, including phage production, the choice of bacteriophage products, phage's administration routes, and the bacterial infection patients that enrolled for phage therapy. In this study, we systematically analyzed the safety problem involved in phage therapy and established the safety assessment system of phage therapy. It can provide basis for phages to enter into clinical therapy in the future.

    参考文献
    [1] Cima G. WHO warns of ‘post-antibiotic era’. Journal of the American Veterinary Medical Association, 2014, 244(12):1356-1357.
    [2] Stone R. Bacteriophage therapy:Stalin's forgotten cure. Science, 2002, 298(5594):728-731.
    [3] Summers WC. The strange history of phage therapy. Bacteriophage, 2012, 2(2):130-133.
    [4] Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, de Corte P, Rose T, Jennes S, Zizi M, de Vos D, Vaneechoutte M. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One, 2009, 4(3):e4944.
    [5] Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans:results of a phase I safety trial. Journal of Wound Care, 2009, 18(6):237-238, 240-243.
    [6] Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrobial Agents and Chemotherapy, 2017, 61(10):e00954-17.
    [7] Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong SL, Donovan DM. Endolysins as antimicrobials. Advances in Virus Research, 2012, 83:299-365.
    [8] Beutin L, Hammerl JA, Strauch E, Reetz J, Dieckmann R, Kelner-Burgos Y, Martin A, Miko A, Strockbine NA, Lindstedt BA, Horn D, Monse H, Huettel B, Müller I, Stüber K, Reinhardt R. Spread of a distinct Stx2-encoding phage prototype among Escherichia coli O104:H4 strains from outbreaks in Germany, Norway, and Georgia. Journal of Virology, 2012, 86(19):10444-10455.
    [9] Chen J, Novick RP. Phage-mediated intergeneric transfer of toxin genes. Science, 2009, 323(5910):139-141.
    [10] Billard-Pomares T, Fouteau S, Jacquet ME, Roche D, Barbe V, Castellanos M, Bouet JY, Cruveiller S, Médigue C, Blanco J, Clermont O, Denamur E, Branger C. Characterization of a P1-like bacteriophage carrying an SHV-2 extended-spectrum β-lactamase from an Escherichia coli strain. Antimicrobial Agents and Chemotherapy, 2014, 58(11):6550-6557.
    [11] Cui ZL, Guo XK, Dong K, Zhang Y, Li QT, Zhu YZ, Zeng LB, Tang R, Li L. Safety assessment of Staphylococcus phages of the family Myoviridae based on complete genome sequences. Scientific Reports, 2017, 7:41259.
    [12] Boratyński J, Syper D, Weber-Dabrowska B, Łusiak-Szelachowska M, Poźniak G, Górski A. Preparation of endotoxin-free bacteriophages. Cellular & Molecular Biology Letters, 2004, 9(2):253-259.
    [13] Boulanger P. Purification of bacteriophages and SDS-PAGE analysis of phage structural proteins from ghost particles//Clokie MR, Kropinski AM. Bacteriophages. Methods in Molecular BiologyTM, vol 502. New York:Humana Press, 2009:227-238.
    [14] Fischer S, Kittler S, Klein G, Glünder G. Impact of a single phage and a phage cocktail application in broilers on reduction of Campylobacter jejuni and development of resistance. PLoS One, 2013, 8(10):e78543.
    [15] Gu JM, Liu XH, Li Y, Han WY, Lei LC, Yang YJ, Zhao HL, Gao Y, Song J, Lu R, Sun CJ, Feng X. A method for generation phage cocktail with great therapeutic potential. PLoS One, 2012, 7(3):e31698.
    [16] Henry M, Lavigne R, Debarbieux L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrobial Agents and Chemotherapy, 2013, 57(12):5961-5968.
    [17] Grønvold AM, L'Abée-Lund TM, Søorum H, Skancke E, Yannarell AC, Mackie RI. Changes in fecal microbiota of healthy dogs administered amoxicillin. FEMS Microbiology Ecology, 2010, 71(2):313-326.
    [18] Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. The ISME Journal, 2007, 1(1):56-66.
    [19] Duerkop BA, Clements CV, Rollins D, Rodrigues JLM, Hooper LV. A composite bacteriophage alters colonization by an intestinal commensal bacterium. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(43):17621-17626.
    [20] Park D, Stanton E, Ciezki K, Parrell D, Bozile M, Pike D, Forst SA, Jeong KC, Ivanek R, Döpfer D, Kaspar CW. Evolution of the Stx2-encoding prophage in persistent bovine Escherichia coli O157:H7 strains. Applied and Environmental Microbiology, 2013, 79(5):1563-1572.
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

崔泽林,郭晓奎,李莉,冯婷婷. 噬菌体抗菌治疗安全性评估体系的建立[J]. 微生物学报, 2018, 58(11): 2033-2039

复制
分享
文章指标
  • 点击次数:1088
  • 下载次数: 2146
  • HTML阅读次数: 2974
  • 引用次数: 0
历史
  • 收稿日期:2018-05-27
  • 最后修改日期:2018-07-13
  • 在线发布日期: 2018-11-06
文章二维码